Invokana, also known by its generic name canagliflozin, is still available on the market. It is prescribed for adults with type 2 diabetes to improve blood sugar control [1].
What is Invokana used for?
Invokana is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [1]. It is also used to reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [1]. Additionally, Invokana is indicated to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and progression of diabetic nephropathy in adults with type 2 diabetes mellitus and albuminuric diabetic kidney disease [1].
Who makes Invokana?
Invokana is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
When was Invokana approved?
Invokana was first approved by the U.S. Food and Drug Administration (FDA) in March 2013 [3].
Are there any major concerns about Invokana?
Invokana carries a boxed warning regarding a potential increased risk of leg and foot amputations [1]. Other serious side effects can include ketoacidosis, severe urinary tract infections, and a rare but serious infection of the tissue in the penis ( Fournier's gangrene) [1]. Patients should be aware of these risks and discuss them with their healthcare provider.
What are the alternatives to Invokana?
Other medications for type 2 diabetes include metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and other SGLT2 inhibitors [4]. The best alternative depends on individual patient needs, other medical conditions, and potential side effects [4].
What is the patent status of Invokana?
Information regarding the patent status and exclusivity of Invokana can be found on DrugPatentWatch.com [5]. Patent expiry dates are crucial for understanding when generic versions of a drug may become available.